^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Rectal Cancer

    Related cancers:
    1d
    SCAR: Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, Zhejiang University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    capecitabine • oxaliplatin • Hetronifly (serplulimab) • celecoxib oral
    1d
    ONCO-RET: Supervised Resistance Training During Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P=N/A, N=15, Not yet recruiting, Fundacion Arturo Lopez Perez
    New trial
    1d
    The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study (clinicaltrials.gov)
    P=N/A, N=8000, Recruiting, UMC Utrecht | Trial completion date: May 2025 --> Aug 2030 | Trial primary completion date: Feb 2024 --> Feb 2030
    Trial completion date • Trial primary completion date
    2d
    Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, Sun Yat-sen University
    New P2 trial • pMMR
    |
    capecitabine • oxaliplatin • Puyouheng (pucotenlimab)
    2d
    Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC (clinicaltrials.gov)
    P2, N=128, Not yet recruiting, Hebei Medical University Fourth Hospital
    New P2 trial • pMMR
    |
    capecitabine • oxaliplatin • Enshuxing (enlonstobart)
    2d
    A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer (clinicaltrials.gov)
    P2, N=52, Completed, Sun Yat-sen University | Recruiting --> Completed | Trial primary completion date: Dec 2025 --> Jul 2025
    Trial completion • Trial primary completion date
    |
    Tyvyt (sintilimab) • capecitabine • oxaliplatin
    2d
    A Study of Tucatinib and Trastuzumab in People With Rectal Cancer (clinicaltrials.gov)
    P2, N=37, Recruiting, Memorial Sloan Kettering Cancer Center | Trial primary completion date: Jun 2026 --> Jul 2027
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase)
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification • RAS wild-type • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type
    |
    Herceptin (trastuzumab) • Tukysa (tucatinib)
    3d
    SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases (clinicaltrials.gov)
    P2, N=42, Recruiting, Fujian Cancer Hospital | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2027 --> Dec 2026 | Not yet recruiting --> Recruiting
    Enrollment open • Trial completion date • Trial primary completion date
    |
    capecitabine • oxaliplatin • Qibeian (iparomlimab/tuvonralimab)
    4d
    High COMP expression promotes tumor cell proliferation and migration of rectal cancer, contributing to unfavorable prognosis and suppressive immune microenvironment. (PubMed, Discov Oncol)
    Collectively, significant higher COMP expression was noticed in public RC cohorts and RC cells, and si-COMP obviously inhibited the cell viability, migration, and invasion, implying its pathogenic role in RC.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • COMP (Cartilage Oligomeric Matrix Protein)
    7d
    Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression (clinicaltrials.gov)
    P2, N=236, Not yet recruiting, Sixth Affiliated Hospital, Sun Yat-sen University | Trial completion date: Nov 2030 --> Mar 2031 | Initiation date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2027 --> Mar 2031
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium
    7d
    Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION) (clinicaltrials.gov)
    P3, N=231, Active, not recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Trial completion date: Mar 2026 --> Mar 2028
    Trial completion date
    |
    AiRuiKa (camrelizumab) • capecitabine • oxaliplatin
    8d
    Expression Profiles and Biomarker Potential of Long Non-Coding RNAs H19, NEAT1, MALAT1 and HOTAIR in Locally Advanced Rectal Cancer Patients. (PubMed, Int J Mol Sci)
    Our results suggest that H19 might be considered as a potential therapeutic target in LARC. Further studies with larger patient groups are required to confirm its diagnostic and prognostic utility.
    Journal
    |
    MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • HOTAIR (HOX Transcript Antisense RNA) • H19 (H19 Imprinted Maternally Expressed Transcript)